The firm's fourth quarter preliminary revenues increased by 11 percent to $865 million year over year, while full-year revenues jumped by 21 percent to $3.3 billion.
Among the firms presenting, 10x noted that it doubled its revenue growth in 2018, and Myriad discussed the impact that new tests are having on its growth.
The tests are designed to detect genetic variations including SNPs, insertion-deletions, copy number variations, and variations in segmental duplications.
The company also said it will release its first polygenic risk score for cardiovascular disease early this year.
The round was led by Meritech Capital, with participation from Fidelity and Wells Fargo, and brings the company's total financing to date to $243 million.
Paragon and MGI Tech — a unit of BGI — have signed a distribution deal for certain of their respective next-generation sequencing panels and sample prep products.
The firms will partner on studies needed to support and secure US regulatory approval for the Elio tissue complete assay.
The company has pivoted to serve the research market but still hopes to spearhead translation of immunotherapy biomarkers following CLIA validation of its approach.
In a letter to CMS, AMP made a case for crosswalking existing CPT codes for BRCA1/2 testing to codes that more accurately reflect the work required to analyze these genes.
Adaptive will use its T-cell receptor screening platform to identify TCRs that can be used to target individual cancer patients' neoantigens.
The companies will integrate PierianDx's informatics solution with two of Illumina's NGS cancer research panels and as well as future IVD products.
The researchers plan to commercialize the method, which they said will help characterize how microbes respond to different environmental conditions.
BabySeq Project researchers reported that genomic sequencing could find even healthy newborns who are at risk of developing childhood-onset conditions.
The index's 13 percent gain was below the 39 percent surge of 2017 but occurred despite the poor performance of index stocks in December.
A new analysis suggests that some mutations that seem to occur in tumors might actually stem from infiltrating blood cells affected by myeloproliferative neoplasms.
Using real-time nanopore metagenomic sequencing, researchers ruled out enhanced human-to-human transmission of Lassa virus during an outbreak in Nigeria last year.
Veracyte plans to launch a new version of its Percepta test and present data for a nasal swab lung cancer diagnostic this year.
PGDx and KingMed plan to provide tumor mutational burden testing to pharmaceutical companies for clinical trials in China and Hong Kong.
A new analysis of transcriptome and tumor growth data uncovered distinct expression-based tumor clusters and treatment responses in males and females.
The San Diego-based company plans to use the funding to support the development of its molecular electronics-based DNA sequencing technology.
Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.
According to Stat News, the partial government shutdown in the US could soon affect the ability of the Food and Drug Administration to review new drugs.
In PNAS this week: gypsy moth genome sequenced, phylogenomic analysis of Polyneopterans, and more.
CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.